PURPOSE: To determine the interrelationships of p53, MDM2, and p14(ARF) protein expression in primary esophageal squamous cell carcinoma (ESCC) and their prognostic value in ESCC. METHODS: In total, 119 patients treated for ESCC with esophagectomy were enrolled in this study. Demographic and clinical data including gender, age, depth of tumor invasion, lymph node involvement, and 5-year survival rate were collected by chart review. p53, MDM2, and p14(ARF) were detected immunohistochemically in the resected tumors to evaluate their usefulness as biomarkers of clinical outcome. RESULTS: p53, MDM2, and p14(ARF) were expressed in 61 (51.3%), 34 (28.6%), and 22 (18.5%) of 119 tumor specimens, respectively. Overall, p53 protein expression was positively correlated with MDM2 (P = 0.024) and p14(ARF) expression (P = 0.026). In addition, p14(ARF) expression was most often found in specimens that were positive for both p53 and MDM2. Changes in the p53, MDM2, and p14(ARF) protein levels were not correlated with 5-year survival rate. CONCLUSIONS: Expression of p53 protein correlates with increased MDM2 and p14(ARF) protein levels in ESCC. In addition, status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14(ARF) is likely to be the more critical determinant of clinical outcome.
PURPOSE: To determine the interrelationships of p53, MDM2, and p14(ARF) protein expression in primary esophageal squamous cell carcinoma (ESCC) and their prognostic value in ESCC. METHODS: In total, 119 patients treated for ESCC with esophagectomy were enrolled in this study. Demographic and clinical data including gender, age, depth of tumor invasion, lymph node involvement, and 5-year survival rate were collected by chart review. p53, MDM2, and p14(ARF) were detected immunohistochemically in the resected tumors to evaluate their usefulness as biomarkers of clinical outcome. RESULTS:p53, MDM2, and p14(ARF) were expressed in 61 (51.3%), 34 (28.6%), and 22 (18.5%) of 119 tumor specimens, respectively. Overall, p53 protein expression was positively correlated with MDM2 (P = 0.024) and p14(ARF) expression (P = 0.026). In addition, p14(ARF) expression was most often found in specimens that were positive for both p53 and MDM2. Changes in the p53, MDM2, and p14(ARF) protein levels were not correlated with 5-year survival rate. CONCLUSIONS: Expression of p53 protein correlates with increased MDM2 and p14(ARF) protein levels in ESCC. In addition, status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14(ARF) is likely to be the more critical determinant of clinical outcome.
Authors: C Capoulade; B Bressac-de Paillerets; I Lefrère; M Ronsin; J Feunteun; T Tursz; J Wiels Journal: Oncogene Date: 1998-03-26 Impact factor: 9.867
Authors: F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters Journal: EMBO J Date: 1998-09-01 Impact factor: 11.598
Authors: A Volant; J B Nousbaum; M A Giroux; I Roué-Quintin; J P Metges; C Férec; H Gouérou; M Robaszkiewicz Journal: J Clin Pathol Date: 1995-06 Impact factor: 3.411
Authors: P Lianes; I Orlow; Z F Zhang; M R Oliva; A S Sarkis; V E Reuter; C Cordon-Cardo Journal: J Natl Cancer Inst Date: 1994-09-07 Impact factor: 13.506
Authors: M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho Journal: Br J Cancer Date: 1997 Impact factor: 7.640